Alimera Sciences (ALIM) Given a $2.00 Price Target at HC Wainwright

Alimera Sciences (NASDAQ:ALIM) received a $2.00 price target from equities researchers at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 88.68% from the stock’s previous close.

A number of other brokerages have also recently issued reports on ALIM. TheStreet upgraded shares of Alimera Sciences from a “d-” rating to a “c-” rating in a report on Tuesday, November 6th. Zacks Investment Research upgraded shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Friday, November 9th. Finally, ValuEngine upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $2.25.

Shares of NASDAQ ALIM opened at $1.06 on Wednesday. The stock has a market cap of $77.09 million, a PE ratio of -3.66 and a beta of 2.17. Alimera Sciences has a 1 year low of $0.72 and a 1 year high of $1.34.

Institutional investors have recently added to or reduced their stakes in the stock. B. Riley Wealth Management Inc. boosted its holdings in Alimera Sciences by 23.5% during the fourth quarter. B. Riley Wealth Management Inc. now owns 101,906 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 19,407 shares during the last quarter. Royce & Associates LP purchased a new position in Alimera Sciences during the third quarter worth about $195,000. BlackRock Inc. boosted its holdings in Alimera Sciences by 28.5% during the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 60,327 shares during the last quarter. Knott David M boosted its holdings in Alimera Sciences by 20.1% during the fourth quarter. Knott David M now owns 387,901 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 65,001 shares during the last quarter. Finally, B. Riley Financial Inc. purchased a new position in Alimera Sciences during the third quarter worth about $447,000. Institutional investors and hedge funds own 52.55% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Recommended Story: Why is the LIBOR significant?

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit